Hideo Kojima’s OD & Physint Was Stalled In 2024, Development To Resume In 2025

Expert Verified By

Both Games Are Currently A Huge Mystery!

Story Highlight
  • The development of Kojima’s upcoming OD and Physint has been stalled this year due to SAG-AFTRA strikes.
  • Hideo Kojima hopes to continue the scanning, casting, and filming process for both games in 2025.
  • OD is expected to be a horror entry, but almost nothing is known about Physint yet.

Kojima Productions is working on games that want to bring innovation to the industry. The studio’s head honcho, Hideo Kojima, has even expressed interest in developing titles that aliens would find cool later on. So it’s no surprise that gamers are highly interested in the upcoming Death Stranding sequel. 

However, little to nothing is known about the status of his other two projects, but he’s finally provided an update.

Hideo Kojima clarifies that OD and Physint are in the earlier stages of development, where the scanning and casting process is done. But recent SAG-AFTRA strikes have thrown a wrench in the plans. 

Why it matters: Hideo Kojima’s new announcement clarifies that SAG-AFTRA strikes have continued to affect the development of games in the industry, potentially delaying OD and Physint for a long time.

Hideo Kojima revealed that development for OD and Physint has been suspended due to this year's SAG-AFTRA Strike.
Hideo Kojima revealed that development for OD and Physint has been suspended due to this year’s SAG-AFTRA Strike.

In a new Twitter post looking back at 2024, Hideo Kojima says that OD has had its actor and environment scanning done already. The rest of the development—along with casting for Physint—had to be suspended because of industry-wide SAG-AFTRA strikes.

He hopes to continue working on both of these games next year. However, the update suggests that we won’t hear much about them for the rest of 2025.

OD is presumably a horror title being developed in partnership with Jordan Peele. Meanwhile, Physint is an upcoming action espionage game in collaboration with Sony.

Overdose
Kojima has described Overdose as a completely new form of media that we’ve never seen.

All in all, Kojima Productions’ Death Stranding 2 is set to launch on PlayStation 5 in 2025. However, it could also appear on Xbox and PC, as per recent speculations.

Do you think Hideo Kojima’s upcoming projects will be able to earn as much recognition as the Death Stranding franchise? Let us know your thoughts in the comments below, or join the discussion on the official Tech4Gamers forum.

Was our article helpful? 👨‍💻

Thank you! Please share your positive feedback. 🔋

How could we improve this post? Please Help us. 😔

Gear Up For Latest News

Get exclusive gaming & tech news before it drops. Sign up today!

Join Our Community

Still having issues? Join the Tech4Gamers Forum for expert help and community support!

Latest News

Join Our Community

104,000FansLike
32,122FollowersFollow

Trending

RPCS3 Hits Optimization Milestone with Up to 7% FPS Boost Across All CPUs

RPCS3 achieves a major milstone boosting PS3 emulation performance by 5-7%, improving FPS, stability, and SPU in demanding titles on all CPUs.

Mass Effect TV Show Undergoing Rewrites To Make it More Accessible For Non-Gamers

Mass Effect TV Show is currently going through major rewrites to make the show more accessible for players who haven't played the games.

Valve Working On A Steam ‘Framerate Estimator’ To Predict How Well A Game Runs Before You Buy

New datamining reveals that Valve is developing a Steam FPS estimator system to predict the amount of FPS each title can get on your PC.

There Are No Plans For New Prototype Game Despite Recent Rumors, Confirms Insider

There are currently no plans for a new Prototype game despite rumors suggesting a new title is indeed in development with Alex Mercer.

50% Of The AI Data Centers In The US Are Cancelled Due To Supply Shortage of Parts From China

Half of the AI Data Centers in the United States are being cancelled due to the supply shortage of parts coming from China.